Guggenheim on Sionna Therapeutics (SION): 'we continue to believe SION has the potential to revolutionize the cystic fibrosis treatment paradigm with its first-in-class NBD1 stabilizers'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $45.00 price target on Sionna Therapeutics (NASDAQ: SION).The analyst comments "Our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
